Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18230731 | 0.85 | PLAU (0.52) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13055383 | 0.82 | LMNA (0.80) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL2840246 | 0.80 | HTT (0.56) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9609127 | 0.79 | PLAU (0.47) | LMNASMN1; SMN2L3MBTL1MAPTPLAU | |
| SCHEMBL5019074 | 0.78 | LMNA (0.73) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL10243339 | 0.76 | LMNA (0.71) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL614872 | 0.76 | LMNA (0.71) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL4506331 | 0.76 | LMNA (0.71) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL6546647 | 0.76 | LMNA (0.71) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL18254066 | 0.76 | HTT (0.81) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145879-B1 | Pyrazine derivatives, methods of use, and methods for preparing same | MEDIBEACON LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2145879-B1 | Pyrazine derivatives, methods of use, and methods for preparing same | MEDIBEACON LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8481734-B2 | Pyrazine derivatives and uses thereof, including in medical imaging and visualization applications | MEDIBEACON DEVELOPMENT LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | MALLINCKRODT INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | DPYD, DHPS, DHX15 | LMNA 2522/4885SMN1; SMN2 2655/4885HTT 1031/4885 |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | DPYD, PRDX5, NOX5 | LMNA 4257/4885SMN1; SMN2 4082/4885HTT 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.